- SAMIL ESG
- Environmental Safety
- Labour and Human Rights
- Mutual Cooperation
- Social Contribution
- Ethical management
- Board of Directors
Board of Directors
The Board of Directors at Samil Pharmaceutical diligently fulfills its responsibilities in compliance with relevant laws, regulations, and the Company’s Articles of Incorporation. The Board is tasked with making key management decisions and effectively overseeing management and directors to act in the best interests of the Company and its shareholders.
Board of Directors
| Name | Experience | Date Appointed | Term | Position |
|---|---|---|---|---|
| SeungBum Huh |
|
2022.03.25 | 3 years |
CEO (Full-time) |
| SangJin Kim |
|
2024.03.22 | 3 years |
CEO (Full-time) |
| TaeKeun Kwon |
|
2023.03.24 | 3 years |
Internal Director (Full-time) |
| JoonBeom Huh |
|
2022.03.25 | 3 years |
Internal Director (Full-time) |
| HyungSeok Choi |
|
2022.03.25 | 3 years |
External Director (Part-time) |
| ChangHo Kim |
|
2022.03.25 | 3 years |
External Director (Part-time) |
| HyungWook Kim |
|
2023.03.24 | 3 years |
External Director (Part-time) |
Committee within the BOD (Audit Committee)
| Classification | Name | Date Appointed | Term | Remarks |
|---|---|---|---|---|
| Audit committee members | HyungSeok Choi | 2022.03.25 | 3 years | External Director |
| ChangHo Kim | 2022.03.25 | 3 years |
External Director (Finance and accounting professional) |
|
| HyungWook Kim | 2023.03.24 | 3 years | External Director |
Current Audit Committee Composition
| Classification | Name | Date Appointed | Term | Experience | Remarks |
|---|---|---|---|---|---|
| Audit committee members | HyungSeok Choi | 2022.03.25 | 3 years |
|
External Director |
| ChangHo Kim | 2022.03.25 | 3 years |
|
External Director | |
| HyungWook Kim | 2023.03.24 | 3 years |
|
External Director |
Audit Opinion for the Last 3 Business Years
| Business Year | Auditors | Audit Opinion | Remarks |
|---|---|---|---|
| 2023 | EY | Adequate | |
| 2022 | EY | Adequate | |
| 2021 | EY | Adequate |
Voting Rights Overview (as of 2023.12.31)
| Classification | Shares | # of Shares | Remarks |
|---|---|---|---|
| Outstanding Shares(A) | Common Shares | 15,226,786 | - |
| Preferred Shares | - | - | |
| Non-Voting Shares(B) | Common Shares | 763,908 | Treasury Shares |
| Preferred Shares | - | - | |
| Shares excluded from exercising voting rights under the Articles of Incorporation(C) | Common Shares | - | - |
| Preferred Shares | - | - | |
| Shares with voting rights restricted by other laws(D) | Common Shares | - | - |
| Preferred Shares | - | - | |
| Shares with voting rights restored(E) | Common Shares | - | - |
| Preferred Shares | - | - | |
| Shares with voting rights(F = A - B - C - D + E) | Common Shares | 14,462,878 | - |
| Preferred Shares | - | - |
Adoption of E-voting, Voting in writing, and Cumulative voting
| Classification | Adopted/Not adopted |
|---|---|
| E-voting and e-proxy | Not adopted |
| Voting in writing | Not adopted |
| Cumulative voting | Not adopted |
Shareholders' Meeting Agenda and Resolutions (Date: 2024.3.22)
| Agenda | Classification | Resolution classification | Approved/Not approved | # of voting rights | # of Shares For (Percentage) | # of Shares Against/Abstained (Percentage) |
|---|---|---|---|---|---|---|
| Agenda #1 | Approval of the financial statements and consolidated financial statements for the 71st period (January 1, 2023 to December 31, 2023) | Ordinary | Approved | 4,765,655 |
4,731,073 (99.27%) |
34,582 (0.73%) |
| Agenda #2 | Appointment of internal directors (Candidate: SangJin Kim) | Ordinary | Approved | 4,765,655 |
4,714,133 (98.92%) |
51,522 (1.08%) |
| Agenda #3 | Determination of the limit on director compensation payments | Ordinary | Approved | 4,765,655 |
4,713,710 (98.91%) |
51,945 (1.09%) |
